Miles, Timothy J., Hennessy, Alan J., Bax, Ben ![]() |
Official URL: http://dx.doi.org/10.1016/j.bmcl.2016.03.106
Abstract
During the course of our research on the lead optimisation of the NBTI (Novel Bacterial Type II Topoisomerase Inhibitors) class of antibacterials, we discovered a series of tricyclic compounds that showed good Gram-positive and Gram-negative potency. Herein we will discuss the various subunits that were investigated in this series and report advanced studies on compound 1 (GSK945237) which demonstrates good PK and in vivo efficacy properties.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Biosciences |
Publisher: | Elsevier |
ISSN: | 0960-894X |
Date of First Compliant Deposit: | 8 May 2018 |
Date of Acceptance: | 29 March 2016 |
Last Modified: | 23 Oct 2022 13:38 |
URI: | https://orca.cardiff.ac.uk/id/eprint/111250 |
Citation Data
Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |